Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus Chemotherapy in First-Line Advanced Gastric, Gastroesophageal, and Esophageal Cancers in US Minority Patients
NCT07554521Phase 2Recruiting
- Sponsor
- BeOne Medicines
- Start
- Apr 2026
- Primary completion
- Dec 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab in gastric adenocarcinoma, gastroesophageal adenocarcinoma and Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by BeOne Medicines. Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at 12 months. Started Apr 2026; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07554521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554521.